MLYS - Company ID 0001933414
The table below shows Mineralys Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$39.47M | -$45.49M | -$19.14M | -$12.78M | -$6.58M |
| Capital expenditure | - | - | - | - | - |
| Investing cash flow | -$44.94M | -$92.88M | -$55.95M | -$140.25M | $0.00 |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - |
Mineralys Therapeutics, Inc. reported operating cash flow of -$142.42M for fiscal year 2025. That is up 14.4% from -$166.31M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Financing cash flow | $24.27M | $189.28M | $116.20M | $203.57M | $12.00M |